Patient perspectives on window of opportunity clinical trials in early-stage breast cancer-Reference-Cited by-同舟云学术

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer

Published:2022-05-11 Issue:1 Volume:194 Page:171-178
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Parikh Divya A.^ORCID,Kody Lisa,Brain Susie,Heditsian Diane,Lee Vivian,Curtis Christina,Karin Mardi R.,Wapnir Irene L.,Patel Manali I.,Sledge George W.,Caswell-Jin Jennifer L.

Funder

U.S. Department of Defense

Agency for Healthcare Research and Quality

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06611-6.pdf

Reference26 articles.

1. Caswell-Jin JL, Lorenz C, Curtis C (2021) Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol 5(1):79–94. https://doi.org/10.1146/annurev-cancerbio-060220-014137

2. Vaz-Luis I, Zeghibe CA, Frank ES et al (2013) Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-013-2717-5

3. Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ (2017) Burdensome research procedures in trials: why less is more. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw315

4. Glimelius B, Lahn M (2011) Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol. https://doi.org/10.1093/annonc/mdq622

5. Robertson JFR, Coleman RE, Cheung KL et al (2020) Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clin Cancer Res 26(7):1574–1585. https://doi.org/10.1158/1078-0432.CCR-19-3053